Achilles adds £100M to move neoantigen T cell therapy into the clinic

Achilles added blue chip investors in its series B round to finance the progression of its neoantigen T cell therapy platform into the clinic.

New investor RA Capital led the £100 million ($121.3 million) series B round for Achilles Therapeutics Ltd. (Stevenage, U.K.). Founding investor Syncona Ltd. (LSE:SYNC) participated, along with additional new investors Forbion Capital Partners, Invus, Perceptive Advisors and Redmile Group...